Index Ventures Announces $2.3bn in New Funds at a Historical Inflection Point for Startups
10.7.2024 07:30:00 EEST | Business Wire | Press release
Index Ventures, a leading global venture capital firm, today announced $2.3 billion in new funds to forge relationships with exceptional entrepreneurs who are creating transformative, category-defining businesses. Combined with Index’s existing $300 million Origin seed fund, Index is deploying $2.6 billion in capital to back founders from seed to IPO. This brings Index’s total capital raised since its founding to $15 billion.
The firm’s fundraise comes at a pivotal moment for the global startup ecosystem. The rise of transformative technologies such as AI, the emergence of tried-and-tested playbooks for hyper-growth companies, and the critical mass of experienced global talent are feeding into and accelerating one another. The result is that entrepreneurs stand at a historical tipping point in which they have unprecedented opportunities to create new, category-defining businesses.
AI opens up entirely new industries for VC investment
“Even though technology has transformed our daily lives, the reality is that it has so much further to go,” said Shardul Shah, partner at Index Ventures. “AI alone will revolutionize virtually every sector of the economy and open up whole industries to venture that have remained virtually untouched. Meanwhile, hundreds of thousands of people have worked in hypergrowth startups globally and can transfer those lessons to the next generation of companies. We’re energized by the unique opportunities that this historical moment presents and excited to partner with founders to solve the world’s trickiest and most consequential problems.”
One global team: from SF to NY, London to Tel Aviv
With its new $800 million venture fund and $1.5 billion growth fund, Index is positioned to be the best long-term partner for entrepreneurs building upon this new foundation wherever they are in the world. Index has a meaningful presence from San Francisco in the West to Tel Aviv in the East – spanning ten time zones and 24 of the world’s 30 most vibrant ecosystems. Established on the West Coast with a portfolio that includes Figma, Discord, Notion, and Roblox, Index has stepped up its US presence with a new New York office. This means it can partner closely with category leaders like Datadog, as well as startups such as Wiz and DataSnipper, using New York as a bridge to help them expand from Europe and Israel across the US. Index has continued strengthening its US leadership by welcoming former Airbnb executive Vlad Loktev to the San Francisco office, who was instrumental in driving Airbnb’s growth and product strategy for over a decade at the company.
Three decades of investing: 108 unicorns, 57 IPOs, 200,000 jobs
Index has a nearly three-decade history of identifying, nurturing, and partnering with visionary founders. Most of these partnerships begin early in a company’s life, at Seed and Series A. Index has invested in 109 companies that reached a $1 billion valuation, 23 that exceeded a $10 billion valuation, and 57 that became publicly traded. The businesses in the Index portfolio have created 200,000 jobs so far and are on track to hire 20,000 more in the next 12 months. Recent highlights from the Index portfolio include:
- Wiz, the cloud security company in which Index was an early investor, grew to 100x its value within 18 months – becoming the fastest-ever company to hit $100m ARR in that time. Wiz has now reached over $350m in ARR and serves over 40% of the Fortune 100;
- Scale AI recently raised $1bn and doubled its valuation to $14 billion, and its data foundry powers nearly every leading large language model;
- DeepL, the language AI company, is transforming the language industry, which is projected to grow to $95.3 billion by 2028. Index led DeepL’s $300M raise at a $2 billion valuation earlier this year;
- Revolut, the all-in-one finance platform, announced revenues exceeding $2.2 billion for 2023, with record pre-tax profits of $545 million and 45 million customers globally
When Index’s founders succeed, they generate outsized returns for the firm’s limited partners, which include non-profit foundations, educational endowments, healthcare and research institutions, and other impact-oriented organizations.
About Index Ventures
Index Ventures is a global venture capital firm that backs exceptional entrepreneurs. We help founders turn their bold ideas into global businesses and, through the companies they build, have a long-lasting and positive impact on the world around us. Index-backed businesses are supported by an experienced team of investors, strategists, and an extensive global network built over three decades of startup investing. Working side-by-side through the scale-up journey, we forge deep and long-lasting relationships with founders and their teams across many industries and geographies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709136755/en/
Contacts
Press Contact:
Kelsey Miller
press@indexventures.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Strong First Half Performance4.8.2026 14:20:00 EEST | Press release
Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of 2026, growing at a combined 8.2% underlying growth rate in local currency. TTI delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion and net profit increasing 17.5% to US$738 million. Our global MILWAUKEE business grew 10.5% on an underlying basis in local currency, after adjusting for the planned 2025 timing impact related to the MILWAUKEE Americas ERP system conversion. RYOBI, the #1 global consumer cordless tool and outdoor products brand, grew 1.7% in local currency to US$1.9 billion in t
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom